Analyst Price Targets — CLOV
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 11, 2026 1:14 pm | Jonathan Yong | UBS | $4.75 | $4.91 | TheFly | Clover Health price target raised to $4.75 from $2.75 at UBS |
| June 4, 2026 10:52 am | Richard Close | Canaccord Genuity | $4.20 | $3.65 | TheFly | Clover Health price target raised to $4.20 from $3.20 at Canaccord |
| October 21, 2025 8:11 am | Whit Mayo | Leerink Partners | $3.00 | $2.92 | StreetInsider | Clover Health (CLOV) PT Raised to $3 at Leerink Partners |
| December 17, 2024 12:18 pm | Matt Hewitt | Craig-Hallum | $6.00 | $3.16 | TheFly | Clover Health initiated with a Buy at Craig-Hallum |
| August 6, 2024 8:17 am | Richard Close | Canaccord Genuity | $2.50 | $1.86 | StreetInsider | Clover Health (CLOV) PT Raised to $2.50 at Canaccord Genuity |
| November 16, 2022 7:51 am | — | Citigroup | $1.80 | $1.44 | Benzinga | Citigroup Maintains Neutral on Clover Health Investments, Lowers Price Target to $1.8 |
Latest News for CLOV
Clover Health Investments said in a regulatory filing on Friday that it detected unusual login activity on some of its information systems on July 4 and later found a hacker had gained access to three employee accounts through social engineering.
WILMINGTON, Del., July 09, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will release its financial results after the market closes on Wednesday, August 5, 2026.
SAN FRANCISCO, July 07, 2026 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover” or “Clover Health”), and a leading AI-powered physician enablement platform, today released findings within the whitepaper “Clinical Excellence in Continuity of Care: A Real-World Analysis of Counterpart Assistant's Role in…
CEO Andrew Toy sold 313,476 shares of Common Stock for a transaction value of ~$1.67 million as of July 1, 2026. This transaction represented 3.16% of Toy's direct holdings, reducing direct ownership to 9,609,825 shares.
Director Carladenise Edwards sold 67,160 shares for a transaction value of approximately ~$230,000 on May 18, 2026, at a weighted average price of around $3.42 per share. This sale represented 19% of her direct holdings at the time, reducing direct ownership from 352,592 to 285,432 shares.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CLOV.
U.S. House Trading
No House trades found for CLOV.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.